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Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by 2	  
the loss of motoneurons in the spinal cord, brainstem and motor cortex. Mutations in the 3	  
superoxide dismutase 1 (SOD1) gene represent a frequent genetic determinant and 4	  
recapitulate a disease phenotype similar to ALS when expressed in mice. Previous studies 5	  
using SOD1G93A transgenic mice have suggested a paracrine mechanism of neuronal loss, 6	  
in which cytokines and other toxic factors released from astroglia or microglia trigger 7	  
motoneuron degeneration. Several pro-inflammatory cytokines activate death receptors 8	  
and may downstream from this activate the Bcl-2 family protein, Bid. We here sought to 9	  
investigate the role of Bid in astrocyte activation and non-cell autonomous motoneuron 10	  
degeneration. We found that spinal cord Bid protein levels increased significantly during 11	  
disease progression in SOD1G93A mice. Subsequent experiments in vitro indicated that Bid 12	  
was expressed at relatively low levels in motoneurons, but was enriched in astrocytes and 13	  
microglia. Bid was strongly induced in astrocytes in response to pro-inflammatory 14	  
cytokines or exposure to lipopolysaccharide. Experiments in bid-deficient astrocytes or 15	  
astrocytes treated with a small molecule Bid inhibitor demonstrated that Bid was required 16	  
for the efficient activation of transcription factor nuclear factor-κB in response to these pro-17	  
inflammatory stimuli. Finally, we found that conditioned medium from wild-type astrocytes, 18	  
but not from bid-deficient astrocytes, was toxic when applied to primary motoneuron 19	  
cultures. Collectively, our data demonstrate a new role for the Bcl-2 family protein Bid as a 20	  
mediator of astrocyte activation during neuroinflammation, and suggest that Bid activation 21	  
may contribute to non-cell autonomous motoneuron degeneration in ALS.    22	  
  23	  
3	  
Highlights: 1	  
• Spinal cords from SODG93A transgenic mice exhibited markedly elevated levels of 2	  
Bid protein  3	  
• Pro-inflammatory conditions increased Bid protein content in astrocytes but not in 4	  
microglia 5	  
• Bid protein participated in the activation of nuclear factor-κB in astrocytes 6	  
• Bid plays a role in non-cell autonomous motoneuron death 7	  
Keywords Amyotrophic Lateral Sclerosis, Astrocyte, Motoneuron degeneration, bid, Bcl-2 8	  
family protein, SOD1G93A, nuclear factor-κB. 9	  
Abbreviations: ALS, Amyotrophic Lateral Sclerosis; APAF1, Apoptotic protease activating 10	  
factor 1, BH3-only protein, Bcl-2 homology domain 3-only protein; bid, BH3 interacting 11	  
domain death agonist; GFAP, glial fibrillary acidic protein; Iba-1, ionized calcium-binding 12	  
adapter molecule 1; IFNγ, interferon-γ; IKK, inhibitor of kappaB kinase; IL-1β, interleukin-13	  
1β; mtSOD1, mutant superoxide dismutase 1; NEMO, NF-kappa-B essential modifier; NF-14	  
κB, nuclear factor-κB; NOD1, nucleotide-binding oligomerization domain containing 1; 15	  
SOD1, superoxide dismutase 1; PND, post-natal day; SMI-32, Sternberger monoclonal-16	  
incorporated antibody 32; tg, transgenic; wt, wild-type 17	  
Acknowledgments: The authors thank Ina Woods for excellent technical assistance and 18	  
Prof A. Strasser (WEHI, Melbourne, Australia) for providing bid-deficient mice.  19	  
Funding: This research was supported by funding from Science Foundation Ireland 20	  
(08/INV.1/B1949) and the Health Research Board (RP/2007/283) to JHMP. SK is 21	  
supported by a Higher Education Authority Program for Research in Third Level 22	  
Institutions (PRTLI) Cycle 5, BIO-AT Ph.D. Scholarship. The funding agencies were 23	  
neither involved in study design, collection, nor analysis or interpretation of data, nor in 24	  
writing of the report, nor in the decision to submit the article for publication. 25	  
Conflict of Interest: The authors declare no conflict of interest.  26	  
4	  
INTRODUCTION 1	  
Amyotrophic Lateral Sclerosis (ALS) is an adult-onset, progressive motoneuron disease 2	  
characterized by degeneration of motoneurons in the motor cortex, brainstem and spinal 3	  
cord ventral horns. Mutations in the copper/zinc superoxide dismutase gene (SOD1) 4	  
account for approximately 20 - 25% of familial ALS patients (Deng et al., 1993; Rosen, 5	  
1993). Over-expression of the human familial ALS-linked SOD1G93A mutations in 6	  
transgenic mouse models (mtSOD1) confer a phenotype similar to ALS patients with motor 7	  
function deficits and a reduced lifespan (Gurney et al., 1994). Although the precise 8	  
mechanisms of motoneuron degeneration in ALS remain largely unidentified, 9	  
proteotoxicity, endoplasmic reticulum stress, glutamate excitotoxicity, oxidative stress, and 10	  
activation of apoptosis have been shown to facilitate motoneuron death in mtSOD1 mice 11	  
and other ALS disease models (Bruijn et al., 2004; Pasinelli and Brown, 2006).  12	  
Apoptosis is a genetically controlled cell death process that is activated by multiple stress 13	  
stimuli. Most forms of stress-induced apoptosis engage the so-called mitochondrial 14	  
apoptosis pathway. This pathway is controlled by the Bcl-2 protein family	   (Youle and 15	  
Strasser, 2008). The Bcl-2 homology domain 3 (BH3)-only proteins are pro-apoptotic 16	  
members of this family. BH3-only proteins are transcriptionally and post-translationally 17	  
activated in neurons in response to stress (Bruijn et al., 2004; Ward et al., 2004), and 18	  
induce apoptosis due to their ability to bind and neutralize anti-apoptotic Bcl-2 family 19	  
proteins	   (Youle and Strasser, 2008). Activation of BH3-only proteins leads to the 20	  
mitochondrial membrane insertion and oligomerization of Bax and Bak (Lovell et al., 2008; 21	  
Tait and Green, 2010). The channels formed by these oligomers constitute release 22	  
channels in the mitochondrial outer membrane, enabling the release of pro-apoptotic 23	  
factors that trigger caspase-dependent and caspase-independent apoptosis. Bax was 24	  
shown to accumulate in mitochondria in animal models of ALS (Guegan et al., 2001), and 25	  
deletion of the bax gene in mtSOD1 transgenic mice inhibited motoneuron death (Gould et 26	  
5	  
al., 2006). Recently it was shown that conditional, combined deletion of bax and bak 1	  
potently delayed disease onset and progression in the SOD1G93A mouse model of ALS	  2	  
(Reyes et al., 2010). BH3-only proteins responsible for the activation of Bax (and 3	  
potentially Bak) in animal models of ALS were also recently identified. The BH3-only 4	  
protein Bim was shown to be transcriptionally up-regulated in response to mtSOD1 over 5	  
expression, and deletion of bim protected against motoneuron loss in mtSOD1 mice in 6	  
vivo (Hetz et al., 2007). We showed recently that endoplasmic reticulum stress was able to 7	  
activate the BH3-only protein Puma in motoneurons, and that deletion of puma protected 8	  
motoneurons against cell death in vitro and in mtSOD1 mice (Kieran et al., 2007).  9	  
Interestingly, several studies also suggest a non-cell autonomous mechanism of 10	  
motoneuron loss in ALS (Ilieva et al., 2009). One possible explanation for a paracrine 11	  
mechanism of motoneuron death is the release of pro-inflammatory or cell death-inducing 12	  
cytokines from non-neuronal cells. Interleukin-1β (IL-1β) and Interferon-γ (IFNγ) have been 13	  
implicated in ALS disease progression (Friedlander et al., 1997; Meissner et al., 2010; 14	  
Wang et al., 2011). Motoneuron apoptosis in ALS was also shown to involve Fas ligand 15	  
up-regulation and activation of Fas death receptors (Locatelli et al., 2007; Raoul et al., 16	  
2002). Release of pro-inflammatory cytokines may lead to death receptor and caspase-8 17	  
activation, which is able to directly activate executioner caspases such as caspase-3 18	  
(Locatelli et al., 2007; Raoul et al., 2002). However, in most cell types, this direct activation 19	  
pathway is not sufficient to activate apoptosis, and an amplification loop is required for cell 20	  
death execution that involves the BH3-only protein Bid, and hence engages the 21	  
mitochondrial apoptosis pathway (Lovell et al., 2008; Luo et al., 1998). Indeed, increased 22	  
expression of Bid in both neurons and astrocytes as well as increased levels of Bid 23	  
cleavage were observed in symptomatic and late stage SOD1G93A mouse spinal cords	  24	  
(Guegan et al., 2002). Interestingly, Bid was recently implicated in the production of pro-25	  
inflammatory cytokines in macrophages and microglia (Mayo et al., 2011) and was 26	  
6	  
reported to be involved in the activation of the transcription factor nuclear factor-κB (NF-1	  
κB) in response to stimulation of pattern recognition receptors in intestinal epithelial cells, 2	  
independent of its direct apoptosis-regulating function (Yeretssian et al., 2011). Therefore, 3	  
in the present study we sought to clarify the role of Bid in the context of neurodegeneration 4	  
and neuroinflammation relevant to ALS. 5	  
7	  
MATERIALS AND METHODS  1	  
Animals 2	  
All experiments described in this study were performed under a license from the 3	  
Department of Health and Children in Ireland (B100/3985) in accordance with the 4	  
European Communities regulations 2010 (2010/63/EU). All procedures were previously 5	  
approved by the Research Ethics Committee of the Royal College of Surgeons in Ireland. 6	  
Transgenic SOD1 mice (mus musculus), IMSR: B6.Cg-Tg (SOD1*G93A) 1Gur/J, with the 7	  
incorporation of the G93A mutant form of human superoxide dismutase (SOD1), were 8	  
purchased from The Jackson Laboratories (JAX, Bar Harbor, Maine, USA). bid–/– mice 9	  
(mus musculus) were generated in the laboratory of Prof. Andreas Strasser, WEHI, 10	  
Melbourne, Australia (Kaufmann et al., 2007). After weaning on postnatal day (PND) 28, 11	  
all pups from litters of the same generation and colony were housed in groups of three to 12	  
five per cage and maintained at 21±1 °C on a 12 h light/dark cycle, (07:00 h on; 19:00 h 13	  
off) with ad libitum access to food and water. 14	  
Reagents and chemicals 15	  
Unless otherwise stated, chemicals were purchased from Sigma-Aldrich (Arklow, 16	  
Ireland) or Merck Chemicals (Nottingham, UK). Cell culture media were purchased from 17	  
Gibco-Life Technologies (Dun Laoghaire, Ireland). BI-6C9 was from Sigma-Aldrich 18	  
(Pubchem: ID 24724408). 19	  
Primary motoneuron cultures 20	  
Primary motoneuron cultures (mixed cultures enriched for motoneurons) were prepared 21	  
from wild-type and bid gene deficient (bid-/-) E12 mouse embryos as described previously 22	  
(Sebastia et al., 2009). Briefly, spinal cords ventral horns were dissected and tissue was 23	  
removed and incubated for 10 min in 0.025% trypsin in Neurobasal media. Cells were 24	  
8	  
transferred into a 0.1 mg/ml DNase1 solution, and gently dissociated. Dissociated 1	  
motoneurons were counted using a hemocytometer and seeded at a density of 105 cells/ml 2	  
onto poly-D,L-ornithine/laminin-coated cell culture wells and maintained at 37°C and 5% 3	  
CO2. Motoneurons were maintained in complete Neurobasal media supplemented with 2% 4	  
horse serum, 2% B27, GDNF (Promega, Cat#2781; 2 ng/mL), CNTF (R&D Systems, 5	  
Cat#557-NT-10, 1 ng/mL), 100 U/mL penicillin and 100 µg/mL streptomycin. Medium was 6	  
changed after 1, 3 and 6 days in vitro (DIV). Cells were cultured up to 14 days. Primary 7	  
motoneuron cultures yielded mixed populations of cells with glial (ca. 40-60%), neuronal 8	  
(ca. 30-40%) and non-neuronal morphology (5-10%); approximately 30-50% of the 9	  
neuronal population were motoneurons positive for the motoneuron marker SMI-32 (Suppl. 10	  
Fig. 3A-A’’).   11	  
Isolation and culturing of primary astrocytes  12	  
Mixed glial cultures were prepared from the cortices of P2 bid-/- and wild-type mice. In 13	  
brief, the cortices were dissected, the meninges removed before incubation in Minimum 14	  
Essential Medium containing 0.025% trypsin and 0.1 mg/ml DNase I for 15 min at 37°C. 15	  
The tissue was triturated mechanically in DMEM to dissociate cells, passed through a 40 16	  
µm nylon cell strainer (BD Falcon, Oxford, UK), and spun at 2,000 rpm for 5 minutes. The 17	  
pellet was resuspended and plated in T75 flasks in DMEM-F12/L-Glutamine containing 1% 18	  
Penicillin/Streptomycin and 10% Fetal Bovine Serum (Sigma-Aldrich). Cells were cultured 19	  
for a minimum of 14 days before being passaged and cultured as astrocytes. For 20	  
astrocyte-enriched cultures, astrocyte flasks were placed on the orbital shaker at 600 rpm 21	  
to shake off microglia; remaining adherent cells were trypsinised and replated for the 22	  
experiment at 5 × 105 cells per 6 well. Motoneuron media was used to generate astrocyte 23	  
conditioned media (ACM) for motoneuron toxicity experiments (Neurobasal media with the 24	  
above mentioned supplements).  25	  
Isolation of primary microglia 26	  
9	  
Microglia were isolated from mixed glial cultures (as above). Following two weeks of cell 1	  
culture, the T75 flasks of confluent mixed glial cultures were shaken in DMEM/F12 at 600 2	  
rpm on a plate shaker for 8 h at room temperature. The supernatant was collected and 3	  
spun down at 2,000 rpm for 5 minutes. The resuspended pellet was plated at a density of 4	  
1 × 105 cells/well of a 24 well plate. The isolated microglia were cultured for 2 days in well 5	  
plates or Millicell-CM inserts (0.4 µm pore size, Fisher Scientific, Dublin, Ireland) in 6	  
DMEM-F12/L-Glutamine, 10% Fetal Bovine Serum and 1% PenStrep (Sigma-Aldrich) 7	  
before treatment.  8	  
Real-Time Quantitative PCR (qPCR) 9	  
RNA was extracted using Qiazol extraction and/or RLT-buffer lysis and RNeasy 10	  
processing according to the manufacturer’s guidelines (Qiagen, Sussex, UK). cDNA 11	  
synthesis was performed based on equal amounts of RNA using the Superscript™ II 12	  
Reverse Transcriptase (Invitrogen, California, USA). qPCR analysis was performed using 13	  
the LightCycler (Roche Diagnostics, Basel, Switzerland) and the QuantiTech SYBR 14	  
Green PCR kit (Qiagen) following manufacturer’s recommendation and standard cycles 15	  
and melting temperatures. The sense and antisense primers for glyceraldehyde-3-16	  
phosphate dehydrogenase (gapdh) were sense 5’-AAC TTT GGC ATT GTG GAA GG-3’, 17	  
antisense 5’-ACA CAT TGG GGG TAG GAA CA-3’; for bid 5’-TCC CCA GAG ACA TGG 18	  
AGA AC-3’ and 5’-GTC GTG TGG AAG ACA TCA CG-3’. RNA levels were normalized to 19	  
gapdh mRNA expression and expressed as n-fold expression over control. For multiplex-20	  
genotyping of human SOD1G93A transgenic mice, primer sequences as described by the 21	  
supplier (Jackson Laboratories, stock# 004435) were used. For bid genotyping, wild-type 22	  
and deleted allele-specific primers using a three-primer strategy as described by 23	  
(Kaufmann et al., 2007) were employed. 24	  
Western blotting and immunoprecipitation 25	  
10	  
Lumbar spinal cord lysates were assessed for Bid protein levels by Western blotting 1	  
following dounce homogenization in RIPA-lysis buffer (Sigma-Aldrich). For Western-blot 2	  
analyses of cell cultures, cells were rinsed with ice-cold PBS and lysed in RIPA lysis buffer 3	  
containing protease inhibitor mix (Sigma-Aldrich). Protein content was determined using 4	  
the BCA Micro Protein Assay kit (Pierce) and samples were supplemented with Laemmli 5	  
sample buffer with 2-mercaptoethanol and denaturated at 95°C for 5 min, followed by 6	  
electrophoresis and Western-blot by standard protocols. Blots were incubated with a rabbit 7	  
polyclonal anti-Bid antibody (1:1000, AR-52, Enzo Life Sciences, Exeter, UK; Cat# ALX-8	  
210-007-R050, AntibodyRegistry (RIID):  AB_2259218), a mouse monoclonal anti-GFAP 9	  
(1:1000, Sigma-Aldrich Cat# G3893, RIID:AB_477010), a goat polyclonal anti-Iba-1 10	  
(1:500, Abcam, Cat# ab5076, RIID:AB_2224402), a rat monoclonal anti-CD11b (1:1000, 11	  
Abcam Cat# ab8878, RIID:AB_306831), a rabbit polyclonal anti-MAP2 (1:1000, Santa 12	  
Cruz Biotechnology, Cat# sc-20172, RIID:AB_2250101), rabbit anti-phosphorylated IKKα/β 13	  
(1:500, 16A6, Cell Signaling Technology, Hitchin, UK, Cat# 2697L, RIID:AB_2291699) and 14	  
anti-IKKα/β (1:500, H470, Santa Cruz Biotechnology, Inc., Cat# sc-7607, 15	  
RIID:AB_675667), a rabbit polyclonal anti-PARP antibody (1:1000, Cell Signaling 16	  
Technology Cat# 9542, RIID:AB_2160739), a rabbit polyclonal anti-caspase-3  (1:1000, 17	  
Cell Signaling Technology Cat# 9662S, RIID:AB_10694681), mouse monoclonal α-tubulin 18	  
(Sigma-Aldrich, Cat# T6199, RIID:AB_477583), and β-Actin (clone AC-40, Sigma-Aldrich, 19	  
Cat# A3853, RIID:AB_262137) antibodies (both 1:5000), a rabbit monoclonal phospho-20	  
Ser536p65 (clone 93H1, CST, Cat# 3033S, RRID:AB_331284), a rabbit monoclonal pan-21	  
p65 (clone D12E12, Cell Signaling Technology Cat# 8242P, RRID:AB_10859369). A goat 22	  
polyclonal anti-Bid (AF860, R&D Systems, Cat# AF860, RIID:AB_2065622) or normal 23	  
goat-IgG (Santa Cruz) were used for immunoprecipitation analyses and captured by 24	  
protein A/G agarose bead slurry (Santa Cruz Biotechnology) following standard protocols. 25	  
Here, following Laemmli-buffer lysis and electrophoreses a rabbit polyclonal anti-IKKγ	  26	  
11	  
(1:500, Abcam Cat# ab77750, RIID:AB_156633) was used for immunodetection. 1	  
Membranes were incubated with the species-specific peroxidase-labeled secondary 2	  
antibodies diluted 1:1000-10,000 (Pierce, Northumberland, UK). Bands were detected 3	  
using Immobilon Western Chemiluminscent HRP Substrate (Fisher Scientific) and imaged 4	  
using a FujiFilm LAS-3000 imaging system (Fuji, Sheffield, UK). Western-blot optical 5	  
densities were determined using standard procedures using ImageJ (NIH; 6	  
imagej.nih.gov/ij) 7	  
Immunofluorescence and microscopy 8	  
Primary cultured neurons were exposed to propidium iodide (2 μg/ml, Sigma Cat#P4864) 9	  
or trypan-blue solution (0.4%, Life Technologies Cat#15250061) prior to fixation in 3% 10	  
paraformaldehyde (PFA, Polyscience, Eppelheim, Germany, Cat#18814-20) diluted in 11	  
cytoskeletal buffer (CB-buffer; 10 mM PIPES pH 6.8, 300 mM NaCl, 10 mM EGTA, 10mM 12	  
glucose, 10mM MgCl2) for 12 minutes. Fixed cells were permeabilized by incubation with 13	  
ice-cold PBS containing 0.1 % (w/v) Triton X-100 and blocked with 0.3 % (w/v) Triton X-14	  
100 and 5 % (v/v) horse serum in PBS. They were incubated overnight in primary antibody 15	  
at 4 °C diluted in PBS / 0.3 % (w/v) Triton X-100 / 3 % (v/v) horse serum. We used a 16	  
mouse monoclonal anti-neurofilament heavy polypeptide (SMI32, 1:1000, Covance, 17	  
Maidenhead, UK, Cat# SMI-32P-100, RIID:AB_10719742), as well as the above 18	  
mentioned p-IKK and GFAP-antibodies. Secondary Alexa-Fluor-488 or -568 coupled 19	  
secondary antibody (1:500, Life Technologies) was incubated for 1 hour at room 20	  
temperature following extensive washes. Cell counts of trypan-blue/PI and SMI-32 labeling 21	  
were performed manually by two experienced experimenters (blinded). Photomicrographs 22	  
were taken using a SPOT RT SE 6 Camera (Diagnostic Instruments, Sterling Heights, MI, 23	  
USA) on an Eclipse TE 300 inverted microscope (Nikon, Kingston upon Thames, UK) with 24	  
Mercury-arc excitation and appropriate filter settings.  25	  
Reporter assays  26	  
12	  
Astrocyte cultures following were transfected using Roche X-tremeGENE HP reagent 1	  
(Roche, Dublin, Ireland) using standard protocols with a mixture of pGL4.32[luc2P/NF-κB-2	  
RE/Hygro] vector (NF-κB-RE, firefly reporter vector, Promega, Southampton, UK, 3	  
Cat#E8491, GenBank:EU581860.1) and a Renilla-luciferase expressing construct under 4	  
constitutive thymidine-kinase promoter control (phRL-TK-luc, Promega, Cat#E6241) at a 5	  
ratio of 14:1 for normalisation. Cultures were washed extensively and transferred back into 6	  
their respective conditioned media for cytokine treatments on the subsequent day. Cells 7	  
were lysed in passive-lysis buffer (PLB, Promega) following the indicated periods of time of 8	  
cytokine or lipopolysaccharide (LPS) treatment in their respective conditioned media, and 9	  
assayed by Dual-luciferase assay (Promega, Cat#E19160) according to the 10	  
manufacturer’s specifications.  11	  
Statistical analysis 12	  
Statistical analyses were performed using PASW statistics 17 software (SPSS, IBM, 13	  
Dublin, Ireland) or GraphPad Prism (GraphPad Software Inc., La Jolla, CA, USA). 14	  
Significance was determined using two-tailed student t-test, or Mann-Whitney U test for 15	  
non-parametric data. For multiple comparisons, one-/two-way ANOVA followed by Holm-16	  
Sidak or Tukeys post-hoc test was used. For non-parametric data, Kruskal-Wallis H test 17	  
test, or Friedmann test for matched data were used, and Dunn's post-hoc test. Grubbs test 18	  
was used to test for outliers. All data are represented as mean ±	  range or mean ±	  SEM. p 19	  
values ≤	  0.05 were considered to be significantly different and marked by an asterisk.  20	  
13	  
RESULTS  1	  
Bid protein levels increase in the SOD1G93A mouse during disease progression 2	  
Bid is constitutively expressed in many central neurons including motoneurons (Krajewska 3	  
et al., 2002), and its activation during apoptosis involves proteolytic cleavage rather than 4	  
transcriptional activation	  (Li et al., 1998; Luo et al., 1998). However, there has was also 5	  
been a report demonstrating increased full-length Bid protein levels during disease 6	  
progression in SOD1G93A mice (Guegan et al., 2002). We therefore started our 7	  
investigation to re-examine the role of Bid regulation during motoneuron degeneration. 8	  
Western blotting analysis of glial-acidic fibrillary protein (GFAP) and Bid protein levels in 9	  
lumbar spinal cord lysates of SOD1G93A mice showed moderately elevated full-length Bid 10	  
protein levels in ‘presymptomatic’ postnatal day (PND) 50 mice, or symptomatic PND 90 11	  
mice, and a pronounced, significant up-regulation in late stage PND 120 SOD1G93A mice 12	  
when compared to their non-transgenic counterparts (Fig. 1A,B; d120: transgenic 13	  
increased by +139.9% ±	   84.62%). Concurrently, GFAP protein levels, likely including 14	  
GFAP splice variants (Kamphuis et al., 2012), increased significantly in vivo (Fig.1A, d120: 15	  
transgenic increased by +685.1% ±	  51.39%). We also detected reduced immunoreactivity 16	  
of the motoneuron marker SMI-32, and moderately up-regulated levels of the microglial 17	  
marker Iba-1 in the lumbar spinal cord of these transgenic animals (Fig.1A). A lack of 18	  
commercially available antibodies that reliably recognize Bid protein levels by 19	  
immunohistochemistry (i.e. that did not show significant non-specific staining in bid-20	  
deficient mice; Suppl. fig. 2A-C,F) prevented us from exploring which cell types expressed 21	  
Bid during disease progression. However, previous reports suggested significant Bid 22	  
immunostaining in both neuronal and non-neuronal cells (Franz et al., 2002; Guegan et al., 23	  
2002). In addition, we failed to collect significant evidence for Bid cleavage in the spinal 24	  
cord of SOD1G93A transgenic animals between day50 and day120 (Suppl. Fig. 1A-D), or 25	  
astrocytes exposed to a pro-inflammatory environment (Suppl. Fig. 1E). 26	  
14	  
Bid is expressed in primary astrocyte and microglia cultures 1	  
To explore whether Bid is also expressed in non-neuronal cells, we investigated Bid 2	  
protein levels by quantitative PCR and Western blotting in murine mixed motoneuron, 3	  
primary astrocyte as well as microglial cultures that were generated using established 4	  
isolation protocols. While motoneuron cultures exhibited moderate bid mRNA (Fig. 2A) and 5	  
protein levels, we noted elevated Bid levels in cultured astrocytes, and an even stronger 6	  
enrichment of Bid protein in microglia-enriched cell cultures (astrocyte over motoneuron 7	  
lysates: increase of 279.5% ±	   23.4%, microglia over motoneuron lysate: increase of 8	  
799.3% ±	  43.5%; Fig. 2B&C). These results suggested that Bid may play a role in the 9	  
regulation of neuroinflammation and astrocyte activation.   10	  
Bid is activated in cultured astrocytes exposed to pro-inflammatory stimuli 11	  
Neuroinflammation is a common hallmark of many neurodegenerative disorders including 12	  
ALS. To determine whether pro-inflammatory stimuli modulate Bid protein levels, we 13	  
treated dissociated astrocyte-enriched cultures with the TLR-agonist lipopolysaccharide 14	  
(LPS 100 ng/ml, 24 h). Western-blot analysis or immunofluorescence labeling revealed a 15	  
remarkable induction of Bid-protein levels in astrocytes treated with LPS (Fig. 3A,B, Suppl. 16	  
fig. 2A,C,D). Spinal cord tissue of ALS mice were shown to have elevated levels of 17	  
secreted interferon-γ (IFNγ, Wang et al., 2011) and interleukin-1β (IL-1β, Meissner et al., 18	  
2010) during pre-symptomatic, symptomatic and end stages. Treatment of mixed 19	  
motoneuron cultures or astrocyte-enriched cultures with IFNγ	   and IL-1β	   resulted in an 20	  
increase of Bid protein to levels comparable to those induced by LPS (Figs. 3C-F, Suppl. 21	  
fig. 2B), meanwhile, GFAP protein levels largely remained unaltered (Fig. 3E). Bid up-22	  
regulation occurred in the absence of astrocyte cell death (data not shown), and elevated 23	  
levels of activated, cleaved caspase-3 or of caspase-3-specific cleavage products of 24	  
PARP-1 were not detectable, demonstrating the absence of an activation of the extrinsic 25	  
or intrinsic apoptosis pathway in astrocytes (Fig. 3G&H). In contrast to our observations in 26	  
15	  
astrocytes or mixed glial or mixed motoneuron cultures (Fig. 3C,I,J, Suppl. Fig. 2D&E), 1	  
exposure of microglia-enriched cultures to LPS or IFNγ/IL-1β did not alter Bid protein 2	  
levels (Fig. 3K-M, Suppl. Fig. 2D), suggesting that Bid is specifically induced in astrocyte 3	  
cultures in response to TLR agonists and pro-inflammatory cytokines. This induction was 4	  
similarly observed in Western-blot and immunofluorescence analyses in purified and 5	  
mixed motoneuron and glial cultures, with the caveat of a high non-specific background 6	  
immunofluorescence present in the bid-deficient astrocytes and tissue seen using three 7	  
distinct full-length Bid-specific antibodies (Suppl. Fig. 2A-C,F). 8	  
Bid negatively modulates nuclear factor-κB activity in cultured astrocytes 9	  
Activation of astrocytes during ALS pathogenesis has been attributed both neuroprotective 10	  
and neurotoxic activities. Bid has was recently been implicated in the control of 11	  
inflammation in intestinal epithelial cells by regulating the activation of the pro-12	  
inflammatory transcription factor nuclear factor-κB (NF-κB) through functional interaction 13	  
with the IKK-complex (Yeretssian et al., 2011). We hence immunoprecipitated LPS-14	  
stimulated astrocyte lysates using Bid anti-serum. In activated cells, Bid markedly 15	  
interacted with the NF-κB essential modulator (NEMO), a critical component of the IKK-16	  
complex (Fig. 4A). Notably, we observed increased levels of IKK-kinase (IKKβ) 17	  
phosphorylation in astrocyte cultures exposed to IFNγ and IL-1β, and this was reduced by 18	  
prior co-application of the Bid-inhibitor BI-6C9 (Fig. 4B). Concomitantly, we also observed 19	  
increased levels of IKK-kinase (IKKβ) and p65 phosphorylation in astrocyte cultures 20	  
exposed to IFNγ and IL-1β	  or LPS, which were not observed in bid-deficient astrocytes 21	  
(Fig. 4B-D). We next investigated whether Bid was implicated in pro-inflammatory 22	  
cytokine-induced NF-κB activation in astrocytes. We monitored the activity of the NF-κB 23	  
transcription factor in reporter gene assays in wild-type and bid-deficient astrocyte 24	  
cultures. Exposure of NF-κB-reporter-gene transfected astrocyte cultures to IL-1β and IFNγ 25	  
demonstrated that pro-inflammatory cytokine-induced stimulation of NF-κB was 26	  
16	  
significantly reduced by co-application of the small molecule Bid inhibitor BI-6C9 (Fig. 4E). 1	  
Likewise, bid-deficiency significantly reduced pro-inflammatory cytokine-induced NF-κB 2	  
activity (Fig. 4F). Furthermore, prolonged exposure of astrocyte cultures to a pro-3	  
inflammatory environment through application of IFNγ and IL-1β for three days to one 4	  
week resulted in a substantial rise in the levels of the NF-κB target gene cyclooxygenase-II 5	  
(COX-II), which was ablated in bid-deficient astrocyte cultures that were free from notable 6	  
CD11b immunoreactivity (Fig. 4G-H).  7	  
bid-deficiency protects against non-cell autonomous motoneuron death 8	  
To explore whether bid-deficiency had functional consequences in the context of non-cell 9	  
autonomous motoneuron death, we treated either wild-type or bid-deficient primary 10	  
astrocyte cultures with LPS or vehicle (saline). After wash-out of LPS, we collected the 11	  
respective astrocyte conditioned media (ACM) and transferred them to wild-type 12	  
motoneuron cultures (Fig. 5A). Motoneuron survival was evaluated by counting SMI-32 13	  
positive neurons that were also negative for propidium iodide and trypan-blue following 14	  
twenty-four hours of incubation (Fig. 5B). Following assessment of mixed motoneuron 15	  
cultures using the additional motoneuron marker HB9 (Arber et al., 1999, Suppl. Fig. 3B-16	  
B’’), we determined that all SMI-32 positive cells in our cultures were NeuN as well as 17	  
HB9-positive motoneurons (Suppl. Fig. 3A’’,B’’) and that SMI-32 represents a stringent 18	  
motoneuron marker in mixed motoneuron cultures (Carriedo et al., 1996). A significant 19	  
decrease in surviving, SMI-32 positive cells was noted following incubation of 20	  
motoneurons with wild-type ACM medium (decreased by 26 ± 19 percent), but not 21	  
following their exposure to medium generated by bid-deficient astrocytes (increased by 6 ± 22	  
15 percent; Fig. 5C). Similarly, we observed a significant increase in survival when 23	  
motoneurons were exposed to the glial-conditioned media (GCM) from bid-deficient 24	  
astrocytes co-cultured with wild-type astrocytes, when compared to wild-type astrocytes 25	  
co-cultured with wild-type microglia (increased by 1.26 ± 0.224 fold, Fig. 5D,E). 26	  
17	  
DISCUSSION  1	  
Mutant SOD1 (mtSOD1) was suggested to cause motoneuron degeneration by impairing 2	  
axonal transport, facilitating protein aggregate production, and sequestering heat-shock 3	  
proteins and anti-apoptotic proteins (Pasinelli and Brown, 2006). The toxicity of mtSOD1 4	  
was also shown to involve non-cell autonomous cell death pathways (Ilieva et al., 2009; 5	  
Lee et al., 2012). Astrocytes expressing mtSOD1 were shown to be a primary source of 6	  
the pro-inflammatory cytokine IFNγ which may directly or indirectly kill neighbouring 7	  
motoneurons (Siegmund et al., 2005; Aebischer et al., 2011; Wang et al., 2011). Increased 8	  
expression of pro-inflammatory cytokines, including IL-1β, IFNγ and IL-6, were a common 9	  
pathological hallmark seen in both transgenic SOD1G93A mice and ALS patients (Li et al., 10	  
2000; Lasiene and Yamanaka, 2011; Wang et al., 2011). Direct administration of IFNγ, or 11	  
IFNγ	  derived from SOD1 mutant astrocytes, induced motoneuron degeneration in vitro in a 12	  
selective and dose-dependent manner (Siegmund et al., 2005; Beers et al., 2006; Boillee 13	  
et al., 2006; Aebischer et al., 2011). On the other hand, neuroinflammatory processes may 14	  
also stimulate tissue regeneration and exert beneficial effects during neurodegeneration 15	  
(Morganti-Kossman et al., 1997; Wyss-Coray et al., 2002; Zhao et al., 2006; Lalancette-16	  
Hébert, 2007). Our data indicate that Bid is induced during neuroinflammation in ALS. We 17	  
observed a marked induction of Bid protein at the symptomatic stage in SOD1G93A mice 18	  
that occurred in parallel with a markedly upregulated GFAP and moderately elevated 19	  
levels of the microglial marker Iba-1. In line with our results, Bid expression was has been 20	  
previously shown to be markedly elevated in both neuronal and non-neuronal cells in the 21	  
SOD1G93A mouse (Guegan et al., 2002), and to correlate with disease severity and 22	  
progression in ALS patients, reaching a maximum at end stage (Guegan et al., 2002). In 23	  
experiments using enriched motoneuron, astrocyte and microglia cultures, we 24	  
demonstrated that Bid was preferentially expressed in astroglia and microglia. We further 25	  
found it was strongly induced in astrocytes upon exposure to pro-inflammatory stimuli, but 26	  
18	  
was not induced in stimulated microglia. Bid was previously shown to be required for death 1	  
receptor-induced apoptosis in numerous cell types, and couples death receptor signaling 2	  
to the mitochondrial apoptosis pathway (Li et al., 1998; Luo et al., 1998; Gross et al., 3	  
1999). While IFNγ and IL-1β themselves do not engage death receptors, it was shown that 4	  
IFNγ-activated microglia induce the expression of the pro-inflammatory cytokine TNF-α	  5	  
and hence may indirectly activate the extrinsic apoptosis pathway. IFNγ may also co-6	  
operate with TNF-α	   to induce oxidative stress (Hanisch, 2002; Mir et al., 2009). 7	  
Additionally, increased Fas ligand expression and activation were identified as key 8	  
mediators of apoptosis in motoneurons during disease progression in the SOD1G93A 9	  
mouse (Raoul et al., 2002; Locatelli et al., 2007). Our data suggest that Bid, in addition to 10	  
a role in death receptor-induced apoptosis of motoneurons, may play a role in non-cell 11	  
autonomous motoneuron death by controlling NF-κB activity in astroglia.  12	  
Our studies revealed that bid-deficiency or the application of a small molecule Bid inhibitor 13	  
significantly reduced LPS-, IFNγ and IL-1β-induced NF-κB activity in astrocytes. 14	  
Suppression of pathologically elevated NF-κB activity in astroglia rather than inhibition of 15	  
death receptor signaling may indeed underlie the protection afforded by astrocyte bid-16	  
deficiency described in this study. The effects of Bid on NF-κB activation in astrocytes 17	  
occurred in the absence of caspase-3 activation, suggesting a non-apoptotic role of Bid in 18	  
this context. Interestingly, suppression of pathologically elevated NF-κB activity has 19	  
repeatedly been linked to improved outcome in CNS injury (Brambilla et al., 2009), sciatic 20	  
nerve injury and ALS	  (Fu et al., 2010; Otsmane et al., 2013). A ‘non-apoptotic’	  function of 21	  
Bid may be in accordance with previous studies that demonstrated a direct influence of Bid 22	  
on NF-κB activity (Luo et al., 2010; Yeretssian et al., 2011). The latter study suggested a 23	  
biological link between the NOD1 (nucleotide-binding oligomerization domain containing 1) 24	  
signalosome and Bid in intestinal epithelial cells, evidenced by co-immunoprecipitation 25	  
between Bid protein, components of the inflammasome and the IκB kinase (IKK)-complex, 26	  
19	  
and a marked deficiency of bid deficient cells to phosphorylate the canonical IKK target 1	  
protein, IκBα. In accordance with these studies, we found activated astrocytes expressed a 2	  
protein complex comprising IKKγ and Bid. However, recently other results have shown 3	  
showed that Bid may not be essential for NOD signaling in other cell types (Nachbur et al., 4	  
2012), suggesting that Bid effects on NF-κB activation are highly context- and tissue-5	  
dependent.  6	  
The pro-inflammatory potency of glial Bid expression may be partially mediated by 7	  
cyclooxygenase-2, a NF-κB-induced mediator of prostaglandin E2 output (Roshak et al., 8	  
1996; Kaltschmidt et al., 2002). Notably, COX-II enzyme is potently up-regulated in the 9	  
ALS-diseased human spinal cord (Yiangou et al., 2006). These results are also in 10	  
agreement with a study showing a non-apoptotic, Bid-dependent activation of COX-II in 11	  
fibroblasts exposed to alkylating agents (Luo et al., 2010). Recently, it was found that bid-12	  
deficient macrophages and microglia also exhibited an impaired ability of pro-inflammatory 13	  
cytokine production (Mayo et al., 2011). It is therefore conceivable that Bid plays a key role 14	  
in the supply of pro-inflammatory cytokines from both microglia and astroglia (Nagai et al., 15	  
2007), thereby amplifying inflammation (Yamanaka et al., 2008). In line with a non-16	  
apoptotic role of Bid, we failed to detect the pro-apoptotic, cleaved form of Bid, tBid, by 17	  
Western blot analyses during disease progression in SOD1G93A mice using three separate 18	  
antibodies detecting either full-length (AF-860 (R&D Systems), AR-52 (Enzo Life 19	  
Sciences); Fig 1A, Suppl. Fig. 1A-C,E), or cleaved Bid (AB10002, EMD Millipore; Suppl. 20	  
Fig. 1D). However tBid is a short-lived protein, which may be difficult to detect.  21	  
In summary, our study highlights a new, non-apoptotic role for astrocytic Bid in the control 22	  
of neuroinflammation, and suggests that Bid activation may contribute to non-cell 23	  
autonomous motoneuron degeneration in ALS.    24	  
20	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24	  
FIGURE CAPTIONS 1	  
Figure 1. Increased Bid protein levels during disease progression in SOD1G93A mice. 2	  
(A) Western blot analysis of full length Bid, GFAP, SMI-32 and Iba-1 protein levels in wild-3	  
type and transgenic SOD1G93A mice at PND120 during the symptomatic stage of ALS 4	  
disease progression (marks highlight GFAP splice variants). (B) Quantification of Bid 5	  
protein levels by Western-blot analyses of non-transgenic (wt) and transgenic SOD1G93A 6	  
(tg) spinal cords pre-symptomatically (PND50), at disease onset (PND90) and during 7	  
disease (PND120). Data are normalized to respective wild-type as well as β-Actin loading 8	  
and represented as mean ±	   range (PND50(n=4/4), PND90(6/6), PND(21/22),*p=0.0462 9	  
(PND120) Mann-Whitney U test).  10	  
Figure 2.  Elevated Bid-protein levels in astroglial cells. (A,B) Dissociated murine 11	  
motoneurons cultures (DIV7), astrocyte-enriched cultures and microglia-enriched cultures 12	  
were lysed in RLT (A, n=3) or RIPA-buffer (B) and mRNA reverse transcribed and 13	  
subjected to real-time PCR analysis using bid- and gapdh specific primers, while proteins 14	  
were separated by gel-electrophoresis. Western-blots were exposed to a rabbit polyclonal 15	  
Bid-antibody, as well as antibodies detecting the neuronal marker protein MAP2, the 16	  
astroglial marker GFAP, and the microglial marker Iba-1. (C) Quantification of Bid protein 17	  
levels compared to motoneuron content was derived from five Western-blot experiments 18	  
(A,C: mean ±	  range). 19	  
Figure 3. Increased Bid levels in astroglial cultures following pro-inflammatory 20	  
treatment. Mouse astroglial (A,B) or mixed glial cultures (composed from 50/50% 21	  
microglial and astroglial cells; I,J)  were treated with 100 ng/ml LPS for twenty-four hours, 22	  
lysed and subjected to Western-blot analyses. (C-F) Mouse motoneuron (C,D) or astroglial 23	  
(E,F) cultures were treated for twenty-four hours with IFNγ (500 U/ml) and IL-1β (50 ng/ml) 24	  
or vehicle in cell culture media and lysates were subjected to gel-electrophoresis and 25	  
Western-blot analyses using the antibodies as indicated. (K-M) Microglia-enriched cultures 26	  
25	  
were cultured for one week and exposed to 100 ng/ml LPS (K,L) or the cytokine mix (M) as 1	  
delineated above and subjected to gel-electrophoresis and Western-blot analyses. 2	  
Quantification of Bid protein levels was derived by optical density analysis from Western-3	  
blot experiments and normalized to loading control (B, n=3; D, n=1, F, n=2; J, n=2; L, n=4; 4	  
mean ±	  range). 5	  
 6	  
Figure 4. Bid-protein functionally interacts with essential components of the IKK-7	  
signalosome and contributes to NF-κB target-gene induction. (A) Murine astrocytes 8	  
were treated for 24 h with the TLR-agonist LPS (100 ng/ml), cells were lysed and 9	  
immunoprecipitated using rabbit-derived anti-Bid antiserum. A notable immunoreactivity 10	  
against NEMO was noted in the immunoprecipitated samples and a concurrently 11	  
decreased NEMO immunoreactivity in the supernatant. Bid immunoreactivity was detected 12	  
using mouse anti-Bid antibodies in the immunoprecipitates. (h.c., heavy-chain) (B) 13	  
Cultured wild-type (wt) or bid-deficient astrocytes were exposed to either vehicle, LPS, or a 14	  
combination of the Bid-inhibitor BI-6C9 (10 µM, 30 min pre-incubation) and LPS for 24 h, 15	  
as indicated. Western-blot membranes derived from the RIPA cell lysates were exposed to 16	  
phosphorylation-specific IKKα/β and p65 antibodies, and pan-IKKα/β, pan-p65 or loading 17	  
control antibodies following membrane stripping. (C) The optical density data from three 18	  
Western-blots of LPS-treated (1-7 days) wild-type (wt) or bid-deficient astrocytes directed 19	  
at phosphorylated IKKβ was determined and normalized to total IKKβ levels (mean ±	  20	  
range). (D) wild-type or bid-deficient astrocytes were exposed for 24 h to LPS, fixed and 21	  
immuno-labeled against phosphorylated-IKKα/β	   (red) and GFAP and S100b (green), as 22	  
indicated.	  (E) Astrocyte cultures, transfected with the κB-dependent reporter gene vector, 23	  
were treated with either IL-1β	  or IL-1β	  (50 ng/ml) + IFNγ (500 U/ml), with or without the Bid-24	  
inhibitor BI-6C9 (100 µM) or respective vehicle, as indicated. The bar graphs represents 25	  
κB-dependent relative firefly activity (n=3-8 from two pooled experiments, one outlier 26	  
26	  
removed, data represents mean ± SEM). (F) Mixed wild-type or bid-deficient astroglial 1	  
cultures were transfected with κB-response element luciferase reporter vectors and 2	  
subsequently treated with IFNγ (500 U/ml) and/or IL-1β	  (50 ng/ml) for 24 h as indicated. A 3	  
significantly decreased level of NF-κB activity in Bid-deficient cells was noted (n=10-16 4	  
wells from three pooled experiments, 1 outlier removed, data represents mean ±	  SEM). 5	  
(G,H) Astrocyte-cultures were grown to confluency, repeatedly stimulated with the pro-6	  
inflammatory cytokine mix every two days for a total of 3 days (G), or one week (H) and 7	  
lysed. Following gel-electrophoresis and Western-blotting, blots were exposed to 8	  
antibodies as indicated. The dotted line indicates intervening lanes have been spliced out. 9	  
(I) Experiments G&H were repeated and the quantified optical densities from a total of n=4 10	  
biological replicates was normalized to loading control and graphed (mean ±	  range).  11	  
 12	  
Figure 5. Bid-protein deficiency ablates the potency of activated astrocytes to kill 13	  
wild-type motoneurons. (A) Diagram describing the collection of activated astrocyte-14	  
conditioned media and their application to motoneuron cultures. (B,C) Wild-type or bid-15	  
deficient astrocytes were treated with 100 ng/ml LPS for 24 hours in astrocyte media. Cells 16	  
were washed extensively and motoneuron media was conditioned on thus activated 17	  
astrocytes for 48 h without further cell stimulus. The media collected from these cells 18	  
(ACM) was applied to wild-type motoneurons for 24 h, cells were exposed to trypan-blue 19	  
solution, fixed and SMI-32 (inset, green) and PI (inset, red) labeled. A potent decrease of 20	  
SMI-32 positive motoneuron density to 74% was recorded following wild-type ACM 21	  
exposure, but motoneurons were potently protected when exposed to bid-/--derived ACM 22	  
(*, p	   ≤	   0.05 for wild-type vs bid-/-, two-way ANOVA, pooled from 2 experiments from 4 23	  
litters, n=8-10 from 4 biological replicates, data represents mean ±	  SEM). Assessment of 24	  
trypan-blue positive cells yielded significantly reduced cell death in bid-deficient cells 25	  
versus wild-type (p=0.0009 for wild-type vs bid-/-, two-way ANOVA, data not shown). Scale 26	  
27	  
bars 50 μm, 10 μm in insets. (D,E) wild-type or bid-deficient astrocytes were co-cultured 1	  
with wild-type microglia as depicted (D) and these mixed cultures were treated with 100 2	  
ng/ml LPS for 24 h in astrocyte media. Cells were washed extensively and motoneuron 3	  
media was conditioned on these activated astrocytes for 48 h without further cell stimulus. 4	  
The media collected from these cells (GCM) was applied to wild-type motoneurons for 48 5	  
h, cells were exposed to trypan-blue solution, fixed and SMI-32 and PI labeled. A 6	  
significant protection was noted of following exposure to bid-/--derived GCM (*, p	  ≤	  0.05, 7	  
one-sided t-test, n=6-7 wells, pooled from 2 biologically separate experiments, data 8	  






Supplementary figure 1 caption. Lack of evidence for Bid cleavage products in inflammatory stimulus exposed neural 
cells or spinal cord tissues following comparison between wild-type and bid-deficient lysates. (A) Wild-type as well as 
bid-deficient brain (br) and spinal cord (sc) samples were collected in RIPA buffer and probed for Bid protein using a 
polyclonal goat (pG) anti-Bid antibody raised against the full-length protein (1:1000; R and D Systems Cat# AF860, An-
tibodyRegistry (RIID):AB_2065622) by Western blot analyses using standard procedures. Anti-Bid immunoreactivity is 
detected at an apparent molecular weight of approximately 22 kDa. Note immunoreactivity of a non-specific band (n.s.) 
at approximately 13-17 kDa in bid+/+, but likewise in lysates from bid-deficient brain and spinal cord samples. A mouse 
anti-a-tubulin antibody was used as loading control mouse monoclonal α-tubulin (1:5000, Sigma-Aldrich, Cat# T6199, 
RIID:AB_477583).  The dotted line denotes intervening bands have been spliced out. (B) End stage SOD1G93A transgenic 
(tg) spinal cord (sc) samples and a bid-/- control sample were sampled for Bid protein analysis by Western blot analysis. 
End stage SOD-tg animals exhibited minimal immunoreactivity below 20 kDa, while a bid-deficient sample exhibited 
marked reactivity at an identical molecular weight. This anti-Bid antibody immunoreactivity was considered non-specific 
in subsequent analyses. (C) Postnatal day (PND) 50 and PND120-derived spinal cord lysates from wild-type as well 
as SOD1-transgenic mice as highlighted were exposed anti-Bid (AR-52), raised against the full length protein (1:1000, 
AR-52, Enzo Life Sciences, Exeter, UK; Cat# ALX-210-007-R050, RIID:  AB_2259218) or a-tubulin antibodies following 
electrophoresis and Western-blot, respectively. Note the minimal immunoreactivity below 17 kDa visible across all indi-
viduals examined. (D) PND120 lysates of wt and tg spinal cord tisse tissue as well as staurosporine-treated (300 nM, 6 
hours) NSC34 cells used as positive control for Bid protein cleavage (pos.), were subjected to 15 % polyacrylamide gel 
electrophoresis and subsequent Western blot followed by exposure to a rabbit anti-mouse Bid cleavage site (59/60) spe-
cific polyclonal antibody (upper panel, 1:500, EMD Millipore Cat# AB10002, RRID:AB_570963), a rabbit anti-mouse Bid 
(middle panel) and anti-mouse β-Actin (lower panel, clone AC-40, 1:5000, Sigma-Aldrich, Cat# A3853, RIID:AB_262137). 
Please note the strong immunoreactivity of a non-specific (n.s.) band that is also present in the bid-deficient tg tissue 
at around 17 kDa, while no immunoreactivity was noted around the apparent molecular weight of the expected 10-15 
kDa of the caspase-8 generated cleavage product (cleav.) of Bid as present in the positive control. (E) Expanded view 
of the anti-Bid blot generated from mixed motoneuron cultures following cytokine exposures as depicted in Figure 3C. 
Prolonged exposure times did not yield any notable Bid-cleavage product-derived immunoreactivity in a range between 
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Supplementary figure 2 caption. Testing antibodies di-
rected at mouse full-length Bid against Bid-deficient cells 
and tissue (A-C) wt- and bid-/- astrocyte cultures were ex-
posed to lipopolysaccharide for 24 h,  fixed in 3% para-
formaldehyde solution for 12 minutes at 37ºC, and sub-
jected to immunofluorescence analyses using the standard 
protocol. The cells were exposed to the antibodies followed 
by standard exposure to fluorescently-labelled secondary 
antibodies, a rabbit polyclonal anti-Bid antibody (A,red, 
1:50, AR-52, Enzo Life Sciences, Exeter, UK; Cat# ALX-
210-007-R050, AntibodyRegistry (RIID):  AB_2259218), 
mouse anti-GFAP/S100b antibodies (A-D, 1:500, both 
green, Sigma Cat# G-A-5, RRID:AB_2314539, mouse 
S100b, 1:500, Sigma, Cat# S2532, RRID:AB_477499), 
a rabbit polyclonal anti-Bid antibody (B,red,1:100, Cat# 
AP06621PU-N, RRID:AB_1611121, a kind sample of Ac-
ris Antikörper GmbH) and a goat polyclonal anti-Bid (C-F, 
AF860, R&D Systems, Cat# AF860, RIID:AB_2065622). 
For the generation of mixed glial cells, astrocytes were 
mixed to 50/50 % with microglial cultures, seeded and fixed 
following the treatments as indicated. These cultures were 
additionally exposed to a rat monoclonal anti-CD11b for 
the labelling of microglia (D, 1:500, Abcam Cat# ab8878, 
RIID:AB_306831). Consider the significant background 
staining observed using all three mouse Bid-specific an-
tibodies in bid-deficient, (non-)treated controls (third col-
umn, A-D) that overall matches - in extent as well as in 
distribution - the immunofluorescence observed in wt-cells 
(first column, A-D). Also note elevated anti-Bid immunoflu-
orescence in some but not all astrocytes treated with cyto-
kine or LPS (A-C) and the strong staining for anti-Bid in the 
microglia compared to the astrocytes in the mixed cultures 
(D), which match the result of higher Bid baseline expres-
sion in microglia than astrocytes obtained in the Western-
blot analyses (Figure 2B&C). The significant background 
immunofluorescence in bid-/- cells suggests a cautious in-
terpretation. A rabbit anti-Hb9 (green, 1:4000, Abcam Cat# 
ab79541, RIID:AB_1603361) and a mouse anti-SMI32 
(1:1000, Covance, Cat#SMI-32P, RIID:AB_10719742), 
both motoneuron markers were used in (E) to mark these 
cells in the mixed motoneuron cultures. Please note the 
moderate elevation of anti-Bid-immunofluorescence in the 
cytokine-treated motoneurons, as well as the astrocytes 
beneath the motoneurons in these mixed cultures. Spinal 
cord (s.c.) motor neurons in situ were labelled in (F) using 
the goat-anti-Bid antibody. Note the slightly lower, but note-
able fluorescence generated following application of this 
antibody to the bid-deficient spinal cord tissue compared 
to the wt tissue that hindered unambiguous assessment 
of Bid expression patterns using this antibody in our spinal 
cord tissues. Treatment regimen concentrations matched 
the concentrations outlined in the main manuscript. 
Hoechst-nuclear labelling is present in all multicolour im-
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Supplementary figure 3 caption. SMI-32 immunolabelling represents a stringent method to high-
light motoneurons in mixed motoneuron cultures. (A) Mixed Motoneuron cultures were maintained 
for ten days in their cell culture media as described. The primary motoneurons were fixed in 3% 
para-formaldehyde solution diluted in cytoskeletal buffer (CB-buffer; 10 mM PIPES pH 6.8, 300 mM 
NaCl, 10 mM EGTA, 10 mM glucose, 10 mM MgCl2) for 12 minutes at 37ºC, and subjected to im-
munofluorescence analyses using the standard protocol. The cells were exposed to the following 
antibodies, a mouse anti-SMI-32 (anti-Neurofilament H Non-Phosphorylated, 1:1000, green, Co-
vance, Inc. Cat# SMI-32P-100, RIID:AB_10719742, a motoneuron marker) and a rabbit anti-NeuN 
(anti-NEUronal nuclei, 1:1000, red, EMD Millipore Cat# ABN78, RIID:AB_10807945, labelling all 
neuronal nuclei). (A’,A’’) Three wells were immunolabelled as above and the fraction of NeuN-
positive cells that were also immunopositive for SMI-32 was determined. Note that all cells found 
positive for SMI-32 were exclusively NeuN immunopositive (A’’) and that a substantial fraction of the 
neuronal cells in culture expressed the SMI-32 antigen (46%, A’). (B) Primary Motoneuron cultures 
were maintained and fixed as above and  exposed to the SMI-32 antibody here combined with a 
rabbit anti-HB9 /HLXB9 specific antibody (motor neuron and pancreas homeobox 1, 1:4000, red, 
Abcam Cat# ab79541, RIID:AB_1603361, a motoneuron marker). (B’,B’’) Three wells were immu-
nolabelled as above and the fraction of HB9-positive cells that were also immunopositive for SMI-32 
was determined. Note that all cells found to express SMI-32 were also labelled by HB9 (B’’), but 
that in turn only a fraction of cells immunopositive for HB9 were co-labelled by SMI-32 (29%, B’). 
Hoechst-nuclear labelling is present in all multicolour images in blue. Scale bar 20 µm.
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